



BactiVac Network

DCVMN Webinar

28 February 2019, 9:00am (GMT+01:00)

Prof Cal MacLennan

Directors: Profs Cal MacLennan & Adam Cunningham











BactiVac: the need





Causes of world-wide deaths


- No vaccines for many globally significant bacterial infections
- Part of solution to antimicrobial resistance (AMR)
- No existing vaccine network focused on bacterial infections







BactiVac: the vision






Accelerating development of vaccines against bacterial infections relevant to LMICs


- Create a sustainable network for vaccine development
- Catalyst project and training funding
- Attract investment/leverage funding for LMICs/UK
- Advocacy for the development of bacterial vaccines



What will BactiVac achieve?



BactiVac: our approach





Support new collaborations through catalyst funds (project and training)

Projects

- Typically £50k for up to 6 months' duration
- Exceptionally £100k for up to 12 months' duration
- Pre-clinical to clinical transition


Training

- Up to £6k available,
- Training visit for up to 3 months' duration

Partnerships (new) to generate preliminary data to go to funding bodies (proof of concept / collaboration)




Bacterial vaccine development pipeline and focus of funding opportunities






BactiVac: our successes





Rapid and continuing growth (18/02/19)







Global reach and engagement

- 671 members in 63 different countries
- 39% members based in LMICs and 11% in industry









BactiVac Members' Directory

- Contains members' profiles Identify potential collaborators
- Network members can access full details (via login)
- Can search by:
 - Name
 - Institution
 - Country
 - Research expertise









BactiVac Inaugural Network meeting

- February 2018, Birmingham
- Speakers from academia, industry and agencies (WHO, Gates, NIBSC)
- 108 delegates attended oversubscribed with a waiting list
- 13 LMIC Travel Bursaries awarded
- All other networks represented

Annual Network Meeting 2019:

20 & 21 March, Birmingham





Catalyst funding: training awards

- Training awards: 5/12 applications funded (totalling £23,052)
- 4/5 successful applicants based in LMICs
- 4 training awards completed





Round 1 training awards

Dr Ritu Amatya

Head of Microbiology Department Nepal Medical College and Teaching Hospital, Nepal

Attendance at ADVAC Course



Dr Birendra Prasad Gupta

Assistant Professor Tropical Disease Research Unit, Tribhuvan University,

Nepal

Training visit to International Vaccine Institute, Seoul. South Korea

To expand knowledge of work on bacterial vaccine clinical trial protocol design to build on existing expertise.



Dr Achut Barakoti

Clinical Microbiologist
Nepal Medical College and Teaching Hospital, Nepal

Attendance at Vaccinology for Public Health & Clinical Practice in 21st Century




Dr Kan Kaneko

Post-doc Researcher Liverpool John Moores University, UK

Training visit to Instituto Butantan, Brazil

To work on antigen production and preparation with a view to further collaborative research on novel vaccine formulations



Dr Shizhong Geng

Associate Professor Yangzhou University, China

Training visit to University of Birmingham, UK
Training in Molecular biology on bacterial vaccines.



Catalyst funding: pump-priming projects

Round 1:

- 12/21 applications funded (£601,414)
 - 9 with LMIC involvement (4 LMIC led)
 - 5 with industry involvement (3 industry led)
 - 1 led by WHO
- Different types of funding leveraged/in-kind contributions:
 - Uncosted PI supervision time (not an allowable cost)
 - ~£42k fEC 20% contribution by UK HEIs
 - ~£190k in-kind contributions
 - Access to data, reagents, lab infrastructure, sample storage, expertise,

mentorship, etc.





Round 1 pump-priming projects

Dr Joseph Campo. Director of Operations Antigen Discovery, Inc. (ADI) (USA)

Protein antibody markers of pneumococcal carriage in support of protein and whole cell vaccine trial design using panproteomic antibody screening.



Read more

Dr Sean Elias, Post-**Doctoral Scientist** University of Oxford (UK)

Measuring non-typhoidal Salmonella specific antibodies in oral fluid as

a non-invasive alternative to serum

Read more

Boris Gavrilov Director **Biologics Development** Facility Huvepharma EOOD (Bulgaria)

Supporting the development of a DIVA compatible glycoconjugate vaccine for brucellosis





Measurement of Shigella-specific

antibodies in the first two years of life in Zambian children to refine correlates of protection and determine the optimal window for vaccination



Professor Daniela Ferreira Reader in Respiratory Infection Immunity and Vaccines Liverpool School of Tropical Medicine (UK)

Identification of correlates of protection against pneumococcal colonization

Read more

Dr Sami Gottlieb Medical Officer World Health Organisation (Switzerland)

Gonococcal Vaccine Preferred Product

Characteristics and Public Health Value Proposition: Initial Global Stakeholder Consultation





Attenuated herepesvirusbased vaccines for lowcost antibiotic-independent

control of bacterial disease in livestock - a proof of concept study



Professor Constantino Lopez-Macias

Principle Investigator Mexican Social Security Institute (Mexico)

Improving the production of a multivalent experimental vaccine against the diseases induced by Salmonella enterica



Read more

Dr Pietro Mastroeni Reader Infection and Immunity University of Cambridge (UK)

Using General Modules for Membrane Antigens

(GMMA) as multivalent Salmonella vaccines for Low-Middle Income Countries (LMIC) and travellers



Dr Christine Rollier Research Scientist University of Oxford (UK)

A novel bivalent vaccine to prevent both Salmonella Typhi and Paratyphi infections: preclinical proof of concept





Read more

Using seroepidemiology of non-Typhoidal Salmonella (NTS) in Kenya to

understand changes in risks of invasion and transmission and direct the clinical development programme for vaccines against NTS



Dr Michelo Simuyandi Research Fellow Centre for Infectious Disease Research in Zambia (Zambia)

Field evaluation and validation of a novel and

rapid ETEC diagnostic assay in a resource limited setting







Catalyst funding: pump-priming projects


Round 2:

- 8/11 applications funded (£477,572)
 - 7 with LMIC involvement (1 LMIC led)
 - 3 with industry involvement
- 1/8 contracts signed so far
- All projects due to start by 1 March 2019

Round 3:

- NOW OPEN
- Submission deadline 5 May 2019
- Funding available from 1 October 2019





Additional funding awarded to BactiVac

- £600k Industry Strategy Challenge Fund (ISCF) Feb 2018
- £1M Department of Health & Social Care (DHSC) Feb 2019





Total BactiVac funding: £3.8M







Network advocacy

- Hosted a visit from UK International
 Development Minister, Alistair Burt 22/02/18
- BactiVac representation at WHO Group A
 Streptococcus Expert Consultation Meeting
- POST Note on vaccines and AMR
- BactiVac 'message' disseminated to >1,500 individuals at key stakeholder meetings (WHO, Bill & Melinda Gates Foundation, Wellcome Trust, NIBSC)
- 986 followers on Twitter










Fantastic panel discussion on how to take forward much needed group A Strep vaccines @BactiVac @WHO #vaccine #savinglives #globalhealth





BactiVac: future





Opportunities

- BactiVac is a conduit to disseminate funding Flexibility
- We are responsive and creative e.g. ISCF, DHSC
- We promote networking our network networks!!
- Collaboration with other MRC/BBSRC/GCRF networks
- Developing partnerships with key stakeholders and policy agencies
- Advocacy brings additional benefits and opportunities
- Need to consider growing long-term future now



How will we continue...

- Grow our membership targeted recruitment:
 - Pathogen gap analysis via PubMed etc
 - Industry via Department for International Trade (DIT), DCVMN
 - Under-represented LMICs via UK Sciences and Innovation Network
- Annual Network Meetings
- Award catalyst project funding:
 - Round 1: monitoring progress, reporting
 - Round 2: contracts awarded, details posted on BactiVac website
 - Round 3: OPEN, closing 5 May, funding available 1 October 2019
- Network advocacy, stakeholder engagement
- Our ambition: to continue building critical mass & influence



Opportunities available through BactiVac


- Join the Network free membership!
- Annual Network Meetings:
 - **2019:** 20 & 21 March, Birmingham, UK
 - 2020: TBC, LMIC setting
 - Travel Bursaries
 - Grant Writing Workshops
- Catalyst project funding:
 - Round 3: OPEN, closes 5 May, 1 October 2019 start
 - Round 4: TBC, Autumn 2019
- Catalyst training awards: open call from March 2019







Work with us.....





www.birmingham.ac.uk/bactivac



BactiVac@contacts.bham.ac.uk



@BactiVac



+44 121 4146973





